公开(公告)号：US20180369404A1

公开(公告)日：2018-12-27

申请号：US15991745

申请日：2018-05-29

Applicant: EpicentRx, Inc.

Inventor： Christopher LARSON ,  Bryan ORONSKY ,  Tony R. REID

IPC: A61K47/68 ,  C12N15/85 ,  A61P35/00 ,  A61K47/69 ,  A61K48/00 ,  C12N15/62 ,  C12N7/02 ,  C12N7/04

Abstract: Disclosed herein are recombinant adenoviruses with one or more nucleotide sequences inserted between two viral transcription units, formulations comprising the recombinant adenoviruses, and methods of treatment using the recombinant adenoviruses. In some embodiments, the one or more nucleotide sequences are inserted in an IX-E2 insertion site and/or an L5-E4 insertion site.

公开(公告)号：US12291726B2

公开(公告)日：2025-05-06

申请号：US18649467

申请日：2024-04-29

Applicant: EpicentRx, Inc.

Inventor： Tony R. Reid ,  Bryan T. Oronsky ,  Christopher Larson

IPC: C12N5/09 ,  C12N7/00

Abstract: The present disclosure relates to compositions and methods for producing a recombinant virus, e.g., a recombinant oncolytic adenovirus, using an A549 host cell.

公开(公告)号：US20250049756A1

公开(公告)日：2025-02-13

申请号：US18930387

申请日：2024-10-29

Applicant: Northrop Grumman Systems Corporation ,  EpicentRx, Inc.

Inventor： Mark D. BEDNARSKI ,  Susan KNOX ,  Louis CANNIZZO ,  Kirstin WARNER ,  Robert WARDLE ,  Stephen VELARDE ,  Shoucheng NING

IPC: A61K31/397 ,  A61K9/00 ,  A61N5/10 ,  C07D205/04

Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.

公开(公告)号：US20240382451A1

公开(公告)日：2024-11-21

申请号：US18570439

申请日：2022-06-16

Applicant: EpicentRx, Inc.

Inventor： Bryan T. ORONSKY ,  Scott CAROEN ,  Tony R. REID

IPC: A61K31/397 ,  A61K45/06 ,  A61P1/00 ,  A61P25/16 ,  A61P25/28 ,  A61P39/00

Abstract: Provided herein are methods of treating and preventing a disorder selected from the group consisting of an autoimmune disorder, inflammatory disorder, immune disorder, bone and joint disorder, neurodegenerative disorder, and neuromuscular disorder in a. subject in need thereof. The method includes administering an effective amount of an organonitro or sulfoxyalkyl organonitro compound to the subject, which may include using a dosing regimen that comprises administering loading and maintenance doses.

公开(公告)号：US20240293360A1

公开(公告)日：2024-09-05

申请号：US18568625

申请日：2022-06-09

Applicant: EpicentRx, Inc.

Inventor： Bryan T. ORONSKY ,  Tony R. REID ,  Christpoher LARSON ,  James KANTER

IPC: A61K31/397 ,  A61K9/14 ,  A61K35/14 ,  A61K47/10 ,  A61P35/00 ,  C07D205/04

CPC classification number: A61K31/397 ,  A61K9/145 ,  A61K35/14 ,  A61K47/10 ,  A61P35/00 ,  C07D205/04

Abstract: The present invention relates to a composition comprising solid crystalline, non-impact or non-detonation sensitive particles comprising 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone (ABDNAZ), methods of preparing the crystalline form, and its use.

公开(公告)号：US20240148692A1

公开(公告)日：2024-05-09

申请号：US18211792

申请日：2023-06-20

Applicant: EpicentRx, Inc.

Inventor： Bryan T. ORONSKY ,  Tony R. REID ,  Arnold ORONSKY

IPC: A61K31/397

CPC classification number: A61K31/397 ,  A61K9/0014

Abstract: Provided herein are therapeutic methods, kits, and pharmaceutical compositions for protecting a subject from radiation using a therapeutic agent selected from the group consisting of RRx-OOI and a pharmaceutically acceptable salt thereof. One exemplary therapeutic method involves administering RRx-OOI to the subject prior to the subject being exposed to the radiation, in order to protect the subject against radiation, such as ionizing radiation containing α-rays, β-rays, γ-rays, neutron radiation, or a combination thereof.

公开(公告)号：US11925617B2

公开(公告)日：2024-03-12

申请号：US17186724

申请日：2021-02-26

Applicant: EpicentRx, Inc. ,  Northrop Grumman Systems Corporation

Inventor： Mark D. Bednarski ,  Susan Knox ,  Louis Cannizzo ,  Kirstin Warner ,  Robert Wardle ,  Stephen Velarde ,  Shoucheng Ning

IPC: A61K31/397 ,  A61K9/00 ,  A61N5/10 ,  A61P9/00 ,  A61P29/00 ,  A61P35/00 ,  A61P35/02 ,  A61P37/06 ,  A61P43/00 ,  C07D205/02 ,  C07D205/04

CPC classification number: A61K31/397 ,  A61K9/0019 ,  A61N5/10 ,  C07D205/04

Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.

公开(公告)号：US20240052016A1

公开(公告)日：2024-02-15

申请号：US18494508

申请日：2023-10-25

Applicant: EpicentRX, Inc.

Inventor： Christopher LARSON ,  Tony R. Reid ,  Bryn T. Oronsky

IPC: C07K14/715 ,  A61P35/00 ,  C07K14/54 ,  C12N15/62

CPC classification number: C07K14/7155 ,  A61P35/00 ,  C07K14/5428 ,  C12N15/62 ,  A61K38/00

Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., an IL-10 trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion protein, or an expression vector encoding for the fusion proteins, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

公开(公告)号：US11744859B2

公开(公告)日：2023-09-05

申请号：US16629099

申请日：2018-07-06

Applicant: EpicentRx, Inc.

Inventor： Bryan T. Oronsky

IPC: A61K36/00 ,  A61K35/16 ,  A61P35/00 ,  A61K31/282 ,  A61K31/337 ,  A61K31/407 ,  A61K31/4745 ,  A61K31/675 ,  A61K31/704 ,  A61K31/7042 ,  A61K35/15 ,  A61K47/46 ,  A61K9/00

CPC classification number: A61K35/16 ,  A61K31/282 ,  A61K31/337 ,  A61K31/407 ,  A61K31/4745 ,  A61K31/675 ,  A61K31/704 ,  A61K31/7042 ,  A61K35/15 ,  A61K47/46 ,  A61P35/00 ,  A61K9/0019

Abstract: The invention provides compositions and methods for administering a therapeutic agent to a patient, such as pharmaceutical compositions containing a blood product and a therapeutic agent selected from an anthracycline anti-cancer agent (e.g., doxorubicin), a topoisomerase inhibitor, an oxazaphosphinanyl anti-cancer agent, a nitro-aryl anti-cancer agent, a thiol-reactive functional group agent, a nitric oxide modulator, a platinum-based antineoplastic compound, acrylamide, acrylonitrile, bis(4-fluorobenzyl)trisulfide, a cardiac glycoside, an anti-mitotic agent (e.g., paclitaxel), a nucleoside analog, an EGFR inhibitor, or an anti-microbial agent.

公开(公告)号：US11253608B2

公开(公告)日：2022-02-22

申请号：US15991745

申请日：2018-05-29

Applicant: EpicentRx, Inc.

Inventor： Christopher Larson ,  Bryan Oronsky ,  Tony R. Reid

IPC: C12N15/85 ,  A61K47/68 ,  A61P35/00 ,  A61K47/69 ,  C12N7/04 ,  A61K48/00 ,  C12N15/62 ,  C12N7/02 ,  C12N15/86

Abstract: Disclosed herein are recombinant adenoviruses with one or more nucleotide sequences inserted between two viral transcription units, formulations comprising the recombinant adenoviruses, and methods of treatment using the recombinant adenoviruses. In some embodiments, the one or more nucleotide sequences are inserted in an IX-E2 insertion site and/or an L5-E4 insertion site.